Crescendo Biologics

Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted immune cell enhancing therapeutics underpinned by its patent-protected Humabody VH platform, which is clinically validated in oncology and immunology. Key platform benefits include rapid discovery, fully human VH domains requiring no humanisation step, exceptional diversity and hit rates, small size enabling access to epitopes unreachable by monoclonal antibodies, and the ability to be assembled into multi-specific MultiBody formats with tunable half-life and multiple administration routes. Beyond its proprietary pipeline, the company maintains global, multi-target discovery and development collaborations with Takeda and BioNTech and an exclusive worldwide licensing agreement with Zai Lab. Crescendo is headquartered on the Babraham Research Campus in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, and Quan Capital.